Glactone Pharma to participate at ACCR Annual Meeting 2016, April 16-20, in New Orleans, USA

2016-04-13

Glactone Pharma will participate at the American Association of Cancer Research (ACCR) Annual meeting which is one of the largest and most important events in the world for researchers in the oncology area.

The company is actively profiling novel small-molecule inhibitors of STAT3 for immuno-oncology and for the treatment of prostate cancer, areas where a STAT3 inhibitor has great potential to address large unmet medical needs and help patients.

Jan Törnell, Chairman of the Board, and Martin Johansson, CEO, will represent the company at the event.

“We are proud to be presenting two posters this year in collaboration with our academic partners and we aim to further strengthen Glactone Pharma’s position as the leader in discovery and development of direct small-molecule STAT3 inhibitors,” said Martin Johansson.

About the posters
Abstract # 555
Presentation Title: Prostate cancer cell-induced differentiation of human monocytes into MDSCs ex vivo is inhibited by targeting STAT3
Presentation Time: Sunday, April 17, 1:00 PM – 5:00 PM
Location: Section 26
Poster Board Number: 16

Abstract # 3342
Presentation Title: Galiellalactone derivative targets stem cell population in ENZ-resistant prostate cancer through inhibition of STAT3
Presentation Time: Tuesday, April 19, 8:00 AM -12:00 PM
Location: Section 32
Poster Board Number: 10

About ACCR
For more information visit the conference website at http://www.aacr.org/MEETINGS/PAGES/MEETINGDETAIL.ASPX?EVENTITEMID=63#

About Glactone Pharma
Glactone Pharma is a biotech company within PULS, a unique Swedish development company in life sciences, and is based on ground-breaking science from the University of Lund in Sweden. Glactone Pharma has developed a pipeline of novel potential drugs that target the STAT3 transcription factor for the use in immuno-oncology and for the treatment of castration resistant prostate cancer (CRPC). STAT3 is directly involved in tumor mediated immune suppression and resistance to androgen inhibition therapy making it an ideal target in combination treatments. To read more about PULS visit www.pulsinvest.se.

For more information
Jan Törnell, Chairman of the Board, Glactone Pharma,
+46 (0)70-676 00 08 or jan.tornell@pulsinvest.se
Martin Johansson, CEO, Glactone Pharma, +1 705 768 0603 or martin.johansson@glactone.com